Phospho-ABL1/ABL2 (Y393/439) Antibody

What is Phospho-ABL1/ABL2 (Y393/439) Antibody and what does it specifically detect?

Phospho-ABL1/ABL2 (Y393/439) Antibody is a highly specific antibody that recognizes ABL1 protein only when phosphorylated at Tyrosine 393 and ABL2 protein only when phosphorylated at Tyrosine 439. This antibody detects endogenous levels of these phosphorylated forms without cross-reactivity to non-phosphorylated versions or other proteins. The antibody specifically binds to the phosphorylated sequence DTYpTA within the activation loop of the kinase domain .

Phosphorylation at these sites correlates with increased kinase activity of ABL1/2 and plays critical roles in signal transduction pathways involving cytoskeleton remodeling, cell adhesion, and migration. The specific detection of these phosphorylation events provides valuable insights into ABL activation status in various biological contexts .

What are the recommended experimental applications for this antibody?

This antibody has been validated for several experimental techniques with specific dilution recommendations:

For optimal results, researchers should determine the ideal working concentration for their specific experimental system through titration experiments .

How does phosphorylation of Y393/439 affect ABL kinase activity and function?

Tyrosine phosphorylation at ABL1-Y393 (equivalent to ABL2-Y439) occurs in the activation loop of the kinase domain and significantly impacts kinase activity. These phosphorylation events are key regulatory mechanisms that:

• Correlate with increased kinase activity by disrupting autoinhibitory interactions within the protein structure

• Are essential for the transforming activity of oncogenic fusion proteins like BCR-ABL1

• Contribute to "constitutively active" ABL mutants that still respond to positive regulation

• Play crucial roles in substrate recognition and enzymatic efficiency

Studies have shown that phosphorylation at these sites disrupts the autoinhibitory SH3 domain–based interactions and intermolecular associations, thereby enhancing kinase activity. This phosphorylation is part of a broader regulatory network involving multiple phosphorylation sites (Y89/Y116, Y245/Y272, Y412/Y439) that collectively determine ABL kinase activity levels .

What are the optimal sample preparation methods for detecting phospho-ABL1/2?

To successfully detect phospho-ABL1/2 (Y393/439), careful sample preparation is critical:

• Cell lysis protocol:

  • Use lysis buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Include protease inhibitors to prevent degradation

  • Maintain cold temperature (4°C) throughout sample processing

• Phosphorylation preservation:

  • Quick sample processing to minimize phosphatase activity

  • Immediate denaturation with SDS sample buffer for Western blotting

  • Fixation with 4% paraformaldehyde for immunostaining within minutes of stimulation

• Enrichment strategies:

  • Consider phosphotyrosine immunoprecipitation before Western blotting for low abundance targets

  • For mass spectrometry analysis, implement dimethyl labeling and immunoaffinity purification as described in phosphoproteomic studies

These methods help maintain phosphorylation status, which is crucial since phosphorylation events can be transient and easily lost during sample preparation .

What are appropriate positive and negative controls for validating antibody specificity?

Proper experimental controls are essential for validating phospho-ABL1/2 (Y393/439) antibody specificity:

Positive controls:

• Cells treated with tyrosine phosphatase inhibitors (pervanadate)

• Cells expressing activated BCR-ABL1 fusion protein

• Cells stimulated with growth factors known to activate ABL (PDGF)

• Lysates from cells with constitutively active ABL kinases

Negative controls:

• Treatment with lambda phosphatase to remove phosphorylation

• Antibody neutralization with immunizing phosphopeptide

• ABL1/2 knockout or knockdown cells

• Cells treated with ABL kinase inhibitors (imatinib)

• Y393F/Y439F mutant proteins to confirm phospho-specificity

For Western blot applications, always include both phosphorylated and non-phosphorylated samples to confirm specific detection of the phosphorylated form .

How can I study ABL1/2 phosphorylation dynamics in response to cellular stimuli?

To effectively study the dynamic phosphorylation of ABL1/2 in response to stimuli:

• Time-course experiments:

  • Establish baseline phosphorylation

  • Create a detailed time series (30 seconds to 24 hours)

  • Rapidly fix or lyse cells to capture transient phosphorylation events

• Stimulus selection:

  • Platelet-derived growth factor (PDGF) is a potent activator of ABL kinases

  • Receptor tyrosine kinase activation (PDGFR-β specifically phosphorylates ABL2)

  • Integrin engagement activates ABL through adhesion-dependent mechanisms

  • B-cell or T-cell receptor stimulation in immune cells

• Quantitative analysis:

  • Use quantitative Western blotting with normalization to total ABL1/2

  • Implement phospho-flow cytometry for single-cell analysis

  • Consider mass spectrometry for site-specific quantification

Research has shown that PDGFR-β directly binds to and phosphorylates the ABL2 SH2 domain, leading to activation of ABL2 kinase activity. This interaction provides a model system for studying stimulus-dependent ABL phosphorylation dynamics .

How does ABL1/2 phosphorylation contribute to cancer progression and metastasis?

ABL1/2 phosphorylation, including at Y393/439 sites, plays significant roles in cancer:

• Oncogenic signaling:

  • Constitutive phosphorylation at Y393/439 correlates with increased kinase activity

  • Activated ABL kinases phosphorylate downstream targets involved in proliferation and survival

  • ABL activation contributes to chemotherapy resistance mechanisms

• Metastatic processes:

  • Phosphorylated ABL1/2 regulates cytoskeletal remodeling necessary for cell motility

  • Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics

  • Regulates cell adhesion and motility by phosphorylating key regulators (CRK, CRKL, DOK1, ARHGAP35)

  • Promotes cell migration through F-actin bundling activity

• Therapeutic implications:

  • ABL kinase inhibitors can potentially target leptomeningeal metastasis in medulloblastoma

  • Phospho-ABL1/2 levels may serve as biomarkers for treatment response

Studies have demonstrated that ABL1 and ABL2 have been implicated in cancer cell migration, invasion, adhesion, metastasis, and chemotherapy resistance, making phosphorylation detection critical for cancer research .

What is the role of ABL1/2 phosphorylation in immune cell function?

ABL1/2 phosphorylation significantly impacts immune cell function through multiple mechanisms:

• T-cell regulation:

  • Positively regulates chemokine-mediated T-cell migration

  • Controls T-cell polarization and homing to lymph nodes

  • Facilitates T-cell response to immune challenges through RAP1 activation

• Phagocytosis:

  • ABL1 phosphorylation regulates complement-mediated phagocytosis

  • ABL2 phosphorylation is required for immunoglobulin-mediated phagocytosis

  • Phosphorylated ABL coordinates actin remodeling necessary for phagocytic cup formation

• B-cell signaling:

  • ABL1 kinase activity and protein levels increase upon B cell receptor (BCR) activation

  • Phosphorylated ABL mediates signaling through BLNK in B cells

Studies using phospho-specific antibodies have revealed that ABL1 and ABL2 act as regulators of multiple immune signaling pathways and their phosphorylation status can be a key indicator of immune cell activation states .

How can I differentiate between ABL1 (Y393) and ABL2 (Y439) phosphorylation?

Differentiating between phosphorylated ABL1 and ABL2 requires specific experimental approaches:

• Immunoprecipitation strategy:

  • First immunoprecipitate with isoform-specific antibodies (anti-ABL1 or anti-ABL2)

  • Then perform Western blot with phospho-ABL1/2 (Y393/439) antibody

  • This sequential approach separates the signals by isoform

• Molecular weight differentiation:

  • ABL1 and ABL2 have slightly different molecular weights

  • Use high-resolution SDS-PAGE (6-8% gels) for better separation

  • ABL1 has a calculated molecular weight of ~122 kDa

  • ABL2 migrates at a slightly different position

• Genetic manipulation:

  • Use ABL1 or ABL2 knockout/knockdown systems

  • Generate cells expressing only one isoform

  • Create Y393F (ABL1) or Y439F (ABL2) mutants as negative controls

If absolute specificity is required, consider using mass spectrometry to identify phosphopeptides unique to each isoform, as the surrounding sequences differ slightly despite the conserved phosphorylation site .

What are the technical considerations for using this antibody in multiplexed immunofluorescence?

When using phospho-ABL1/2 (Y393/439) antibody in multiplexed immunofluorescence:

• Antibody compatibility:

  • Confirm host species compatibility with other primary antibodies

  • Use isotype-specific secondary antibodies to prevent cross-reactivity

  • Consider using directly conjugated antibodies for complex multiplexing

• Signal optimization:

  • Implement sequential staining protocols for phospho-epitopes

  • Use tyramide signal amplification for weak phospho-signals

  • Optimize antibody concentration (1:100-1:200 recommended for IF)

• Controls and validation:

  • Include single-stained controls to assess bleed-through

  • Use spectral unmixing for overlapping fluorophores

  • Validate colocalization with total ABL1/2 antibodies

• Sample preparation:

  • Optimize fixation to preserve phospho-epitopes (4% PFA recommended)

  • Consider antigen retrieval methods suitable for phospho-epitopes

  • Implement phosphatase inhibitor treatment during sample preparation

These approaches will help achieve specific detection while minimizing background and cross-reactivity when examining phospho-ABL1/2 alongside other markers .

How can I study the relationship between ABL1/2 phosphorylation and substrate selection?

To investigate how Y393/439 phosphorylation affects ABL1/2 substrate selection:

• Phosphorylation-dependent substrate profiling:

  • Compare substrates phosphorylated by wild-type versus constitutively active ABL

  • Use phosphoproteomic approaches with dimethyl labeling

  • Implement ATP analog-sensitive ABL mutants for direct substrate identification

• Processive phosphorylation analysis:

  • ABL kinases exhibit "processive phosphorylation" where the SH2 domain binds to phosphorylated sites

  • This mechanism increases phosphorylation efficiency of multi-target proteins

  • Study how Y393/439 phosphorylation affects this process using sequential phosphorylation assays

• Substrate consensus determination:

  • Analysis of 119 validated ABL1/2 substrates confirms preference for proline at position +3

  • Y393/439 phosphorylation may alter this preference

  • Use peptide arrays to compare substrate preferences of phosphorylated vs. non-phosphorylated ABL

Research has shown that the ABL SH2 domain contributes to catalytic activity and target site specificity, with phosphorylation status potentially affecting these interactions through conformational changes .

What are the methodological considerations for studying ABL1/2 phosphorylation in neurodegenerative diseases?

When investigating ABL1/2 phosphorylation in neurodegenerative disease contexts:

• Tissue preparation:

  • Rapid post-mortem preservation is critical for phospho-epitope retention

  • Optimize fixation protocols for brain tissue (brief fixation times)

  • Consider alternative fixatives to paraformaldehyde for better phospho-epitope preservation

• Disease-specific considerations:

  • In Parkinson's disease, examine ABL-mediated phosphorylation of α-synuclein

  • For Alzheimer's disease, investigate ABL activation in relation to tau pathology

  • Compare phosphorylation patterns between affected and unaffected brain regions

• Analytical approaches:

  • Use immunohistochemistry to localize phospho-ABL1/2 relative to disease markers

  • Implement laser capture microdissection for region-specific Western blot analysis

  • Consider phospho-flow cytometry for isolated primary neurons

Research has shown that Abl kinases phosphorylate multiple proteins implicated in neurodegenerative diseases, including α-synuclein, Cdk5, and DARPP-32, making the detection of phosphorylated ABL crucial for understanding disease mechanisms .

How can phospho-ABL1/2 detection be integrated into high-throughput screening platforms?

For incorporating phospho-ABL1/2 (Y393/439) detection into high-throughput screens:

• Assay formats:

  • Develop cell-based ELISA in 96/384-well formats

  • Implement high-content imaging with automated phospho-ABL1/2 detection

  • Create homogeneous assays using phospho-specific antibodies with proximity-based detection

• Validation strategy:

  • Use known ABL inhibitors as positive controls

  • Include phosphatase treatments as negative controls

  • Validate hits with orthogonal phosphorylation detection methods

• Implementation considerations:

  • Optimize cell density and stimulation conditions for maximum signal-to-noise ratio

  • Determine Z-factor to ensure assay robustness

  • Develop automated image analysis algorithms for phospho-ABL1/2 localization

• Data analysis:

  • Normalize phospho-ABL1/2 signals to total ABL protein

  • Implement machine learning for pattern recognition in complex phenotypes

  • Develop dose-response curves for promising compounds

These approaches enable efficient screening of compounds that modulate ABL1/2, which could have therapeutic potential in cancer, neurodegeneration, and inflammatory conditions .

What are the best practices for studying phospho-ABL1/2 in primary patient samples?

When working with primary patient samples to detect phospho-ABL1/2:

• Sample handling:

  • Process samples immediately to preserve phosphorylation status

  • Use stabilization buffers containing phosphatase inhibitors

  • Implement snap-freezing protocols for samples that cannot be processed immediately

• Clinical sample considerations:

  • For blood samples, isolate mononuclear cells using density gradient centrifugation

  • Process fresh tissue samples within 30 minutes of collection

  • Consider using phosphatase inhibitors during surgical specimen collection

• Detection methods:

  • For limited samples, use highly sensitive techniques like proximity ligation assay

  • Consider multiplexed analysis to maximize information from scarce samples

  • Implement laser scanning cytometry for rare cell populations

• Controls and normalization:

  • Include matched normal tissues when available

  • Use surrogate phosphorylation markers to confirm sample quality

  • Normalize to housekeeping proteins and total ABL protein levels

These approaches help overcome the challenges of phospho-protein detection in clinical samples, where pre-analytical variables can significantly impact results .

How does the phosphorylation of ABL1/2 influence drug resistance in cancer therapy?

Phosphorylation of ABL1/2 plays critical roles in drug resistance mechanisms:

• BCR-ABL mutations and phosphorylation:

  • Phosphorylation at Y393/439 correlates with BCR-ABL transforming activity

  • Even "constitutively active" ABL mutants respond to additional positive regulation through phosphorylation

  • Phosphorylation status can predict response to tyrosine kinase inhibitors

• Compensatory pathways:

  • ABL1/2 phosphorylation may activate alternative signaling pathways

  • Phosphorylated ABL can mediate resistance through activation of downstream targets

  • Y393/439 phosphorylation may serve as biomarkers for resistance development

• Monitoring approaches:

  • Serial monitoring of phospho-ABL1/2 during treatment

  • Correlation with clinical response and resistance development

  • Implementation of phospho-specific flow cytometry for real-time monitoring

• Combination therapies:

  • Target phosphorylation-dependent interactions with combination approaches

  • Block compensatory pathways activated by phosphorylated ABL

  • Develop strategies to overcome resistance based on phosphorylation status

Understanding the dynamics of ABL1/2 phosphorylation provides insights into resistance mechanisms and may inform personalized treatment approaches for patients with ABL-driven malignancies .